Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | THRB | P10828 | 8/20 | 1.00 |
| ▸ | BLM | P54132 | 8/20 | 1.00 |
| ▸ | RECQL | P46063 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | S100A4 | P26447 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | STAT6 | P42226 | 4/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxorubicin SCHEMBL317301 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL9335136 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL6251124 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL3242 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL571906 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL317302 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL6423994 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL57097 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21669731 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21669733 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3021 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023222019-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | 成都百利多特生物药业有限责任公司 | 2023-11-23 | — | — | WO | claimed |
| WO-2023141560-A2 | ALKALINE PHOSPHATASE FOR USE IN ONCOLOGY | SYNTHETIC BIOLOGICS, INC. (US) | 2023-07-27 | — | — | WO | claimed |
| US-20220298252-A1 | METHODS OF TREATING CANCER USING TNFRSF25 ANTIBODIES | PELICAN THERAPEUTICS, INC. | 2022-09-22 | — | — | US | claimed |
| EP-4021494-A1 | METHODS OF TREATING CANCER USING TNFRSF25 ANTIBODIES | Pelican Therapeutics, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| US-20220185863-A1 | COMBINATION THERAPIES | SHATTUCK LABS, INC. | 2022-06-16 | — | — | US | claimed |
| CN-114502195-A | Methods of treating cancer using TNFRSF25 antibodies | 派立卡恩治疗公司 | 2022-05-13 | — | — | CN | claimed |
| WO-2022081521-A1 | INOSITOL-BISPYROPHOSPHATE-DERIVED COMPOUNDS AND USES THEREOF | NICOLAU YVES CLAUDE (US) | 2022-04-21 | — | — | WO | claimed |
| EP-3930851-A1 | COMBINATION THERAPIES | Shattuck Labs, Inc. (US) | 2022-01-05 | — | — | EP | claimed |
| CN-113747947-A | Combination therapy | 沙塔克实验室有限公司 | 2021-12-03 | — | — | CN | claimed |
| EP-3876988-A1 | CDCP1-TARGETED THERAPIES | Beth Israel Deaconess Medical Center (US) | 2021-09-15 | — | — | EP | claimed |
| EP-3773686-A1 | ALKALINE PHOSPHATASE AGENTS FOR TREATMENT OF RADIATION DISORDERS | Synthetic Biologics, Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| US-20210023182-A1 | ALKALINE PHOSPHATASE AGENTS FOR TREATMENT OF RADIATION DISORDERS | THERIVA BIOLOGICS, INC. | 2021-01-28 | — | — | US | claimed |
| US-20200405778-A1 | MICROBIOME RELATED IMMUNOTHERAPIES | FINCH THERAPEUTICS HOLDINGS LLC | 2020-12-31 | — | — | US | claimed |
| EP-3755353-A1 | MICROBIOME RELATED IMMUNOTHERAPIES | Crestovo Holdings LLC (US) | 2020-12-30 | — | — | EP | claimed |
| CN-112067805-A | Application of beta-1, 4-galactosyltransferase-IsiRNA in drugs for overcoming drug resistance of liver cancer chemotherapy | 南通大学 | 2020-12-11 | — | — | CN | claimed |
| WO-2019183209-A1 | ALKALINE PHOSPHATASE AGENTS FOR TREATMENT OF RADIATION DISORDERS | SYNTHETIC BIOLOGICS, INC. (US) | 2019-09-26 | — | — | WO | claimed |
| WO-2019165285-A1 | MICROBIOME RELATED IMMUNOTHERAPIES | CRESTOVO HOLDINGS LLC (US) | 2019-08-29 | — | — | WO | claimed |
| WO-2016073733-A1 | METHODS OF TREATING CANCER USING LIPOPEPTIDES | CLEVELAND BIOLABS, INC. (US) | 2016-05-12 | — | — | WO | claimed |
| US-8461178-B2 | Naphthyridine derivatives and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2013-06-11 | — | — | US | claimed |
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |